Key information

🔎 Fund Overview

GRI Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Its therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as an oral therapeutic for the treatment of idiopathic pulmonary fibrosis (IPF). Its product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. The Company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) or lupus and multiple sclerosis (MS).